Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis

Arthritis and Rheumatism

Volumn 65, Issue 7, 2013, Pages 1684-1693

  Knevel, R ^a   De Rooy, D P C ^a   Zhernakova, A ^a,b   Grondal G ^c   Krabben, A ^a   Steinsson, K ^c   Wijmenga, C ^b   Cavet, G ^d   Toes, R E M ^a   Huizinga, T W J ^a   Gregersen, P K ^e   Van Der Helm Van Mil, A H M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^d Crescendo Bioscience   (United States)

^e FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; INTERLEUKIN 2 RECEPTOR ALPHA; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HERITABILITY; HUMAN; ICELAND; INTRON; JOINT DESTRUCTION; MAJOR CLINICAL STUDY; NORTH AMERICA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ARTHRITIS, RHEUMATOID; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOOT JOINTS; GENETIC PREDISPOSITION TO DISEASE; HAND JOINTS; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LONGITUDINAL STUDIES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84879876338     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.37938     Document Type: Article

References (48)

1. Symmons D, Turner G, Webb R, Asten P, Barrett E, Lunt M, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41: 793-800.
2. Radner H, Smolen JS, Aletaha D,. Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 381-8.
3. Van der Heijde DM,. How to read radiographs according to the Sharp/van der Heijde method [corrected and republished in J Rheumatol 2000;27:261-3]. J Rheumatol 1999; 26: 743-5.
4. Van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB,. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis: a prospective follow-up study of 147 patients. Br J Rheumatol 1992; 31: 519-25.
5. Visscher PM, Brown MA, McCarthy MI, Yang J,. Five years of GWAS discovery. Am J Hum Genet 2012; 90: 7-24.
6. Knevel R, Grondal G, Huizinga TW, Visser AW, Jonsson H, Vikingsson A, et al. Genetic predisposition of the severity of joint destruction in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2012; 71: 707-9.
7. Scherer HU, van der Linden MP, Kurreeman FA, Stoeken-Rijsbergen G, le Cessie S, Huizinga TW, et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2010; 69: 567-70.
8. Kurreeman FA, Padyukov L, Marques RB, Schrodi SJ, Seddighzadeh M, Stoeken-Rijsbergen G, et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis [published erratum appears in PLoS Med 2007;4:e358]. PLoS Med 2007; 4: e278.
9. Van der Linden MP, Feitsma AL, le Cessie S, Kern M, Olsson LM, Raychaudhuri S, et al. Association of a single-nucleotide polymorphism in CD40 with the rate of joint destruction in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2242-7.
10. Knevel R, Krabben A, Brouwer E, Posthumus MD, Wilson AG, Lindqvist E, et al. Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multi cohort study. Ann Rheum Dis 2012; 71: 1651-7.
11. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75: 330-7.
12. Plenge RM, Padyukov L, Remmers EF, Purcell S, Lee AT, Karlson EW, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77: 1044-60.
13. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39; 1477-82.
14. Thomson W, Barton A, Ke X, Eyre S, Hinks A, Bowes J, et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007; 39: 1431-3.
15. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357: 977-86.
16. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis-a genomewide study. N Engl J Med 2007; 357: 1199-209.
17. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
18. Zhernakova A, Alizadeh BZ, Bevova M, van Leeuwen MA, Coenen MJ, Franke B, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81: 1284-8.
19. Barton A, Thomson W, Ke X, Eyre S, Hinks A, Bowes J, et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008; 40: 1156-9.
20. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burtt NP, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40: 1216-23.
21. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, et al. REL, encoding a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009; 41: 820-3.
22. Raychaudhuri S, Thomson BP, Remmers EF, Eyre S, Hinks A, Guiducci C, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41: 1313-8.
23. Stahl EA, Raychaudhuri S, Remmers EF, Xie G, Eyre S, Thomson BP, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42: 508-14.
24. Van Nies JA, Knevel R, Daha N, van der Linden MP, Gregersen PK, Kern M, et al. The PTPN22 susceptibility risk variant is not associated with the rate of joint destruction in anti-citrullinated protein antibody-positive rheumatoid arthritis. Ann Rheum Dis 2010; 69: 1730-1.
25. Teare MD, van der Helm-van Mil AH, Moore DJ, Knevel R, Kleszcz A, Huizinga TW, et al. Identification and validation of a novel marker for radiological severity in RA [abstract]. Ann Rheum Dis 2011; 70 Suppl 3: 146.
26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
27. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes-what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
28. Sharp JT, Wolfe F, Mitchell DM, Bloch DA,. The progression of erosion and joint space narrowing cores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 1991; 34: 660-8.
29. Wolfe F, Michaud K,. The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) 2011; 50: 16-24.
30. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, Szperl A, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011; 43: 1193-201.
31. Marchini J, Howie B, Myers S, McVean G, Donnelly P,. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906-13.
32. Lowe CE, Cooper JD, Brusko T, Walker NM, Smyth DJ, Bailey R, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39: 1074-82.
33. Fitzmaurice GM, Laird NM, Ware JH,. Overview of linear models for longitudinal data. In: Applied longitudinal analysis. Hoboken (NJ): John Wiley & Sons; 2004. p. 49-88.
34. Lebrec JJ, Stijnen T, van Houwelingen HC,. Stat Appl Genet Molecular Biol 2010; 9: art 8.
35. Waldmann H,. Immunology: protection and privilege. Nature 2006; 442: 987-8.
36. Dendrou CA, Plagnol V, Fung E, Yang JH, Downes K, Cooper JD, et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009; 41: 1011-5.
37. Hinks A, Barton A, John S, Bruce I, Hawkins C, Griffiths CE, et al. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum 2005; 52: 1694-9.
38. Vella A, Cooper JD, Lowe CE, Walker N, Nutland S, Widmer B, et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005; 76: 773-9.
39. Qu HQ, Montpetit A, Ge B, Hudson TJ, Polychronakos C,. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007; 56: 1174-6.
40. Matesanz F, Caro-Maldonado A, Fedetz M, Fernandez O, Milne RL, Guerrero M, et al. IL2RA/CD25 polymorphisms contribute to multiple sclerosis susceptibility. J Neurol 2007; 254: 682-4.
41. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN), Harley JB, Alarcon-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008; 40: 204-10.
42. Brand OJ, Lowe CE, Heward JM, Franklyn JA, Cooper JD, Todd JA, et al. Association of the interleukin-2 receptor α (IL-2Rα)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin Endocrinol (Oxf) 2007; 66: 508-12.
43. Maier LM, Lowe CE, Cooper J, Downes K, Anderson DE, Severson C, et al. IL2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet 2009; 5: e1000322.
44. Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu DV, et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009; 182: 1541-7.
45. Robb RJ, Kutny RM,. Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein. J Immunol 1987; 139: 855-62.
46. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, et al. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor α-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007; 56: 965-71.
47. Makis AC, Galanakis E, Hatzimichael EC, Papadopoulou ZL, Siamopoulou A, Bourantas KL,. Serum levels of soluble interleukin-2 receptor α (sIL-2Rα) as a predictor of outcome in brucellosis. J Infect 2005; 51: 206-10.
48. Wuest SC, Edwan JH, Martin JF, Han S, Perry JS, Cartagena CM, et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011; 17: 604-9.